Breaking News, Trials & Filings

Gilead’s Phase 2 Trodelvy/KEYTRUDA Study Shows Promise in NSCLC

Preliminary data supports ongoing Phase III trial of Trodelvy in combination with KEYTRUDA in first-line metastatic NSCLC.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Gilead Sciences, Inc. reported promising early data from the global, open-label, Phase 2 EVOKE-02 study evaluating Trodelvy (sacituzumab govitecan-hziy) in combination with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) with or without platinum agents in patients with previously untreated advanced or metastatic non-small cell lung cancer (NSCLC). Preliminary analysis of the study includes results of two cohorts: Trodelvy in combination with KEYTRUDA in first-line advanced or metastatic sq...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters